This week's roundup of Houston innovators includes Lacey Tezino of REACH, Prabhdeep Singh Sekhon of Gold H2, Jill Chapman of Insperity. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a podcast with the new CEO of a gold hydrogen biotech company, the leader of a health tech program, and an HR expert.


Lacey Tezino, program manager at the Gulf Coast Consortium's Research Evaluation and Commercialization Hub

According to program manager Lacey Tezino, REACH received 31 applications over the course of a month last fall. Photo courtesy

A group of seven groundbreaking scientists has been chosen as the first cohort of a top-flight new program for medical innovators.

Last year, the National Institute of Health (NIH) awarded theGulf Coast Consortium with a $4 million grant. Its use? The Research Evaluation and Commercialization Hub, known as REACH. REACH combines the powers of one of the world’s largest inter-institutional cooperatives — including eight Houston-area medical research organizations— to help accelerate fledgling innovations.

According to program manager Lacey Tezino, REACH received 31 applications over the course of a month last fall.

“They were really solid applications. I was just like, ‘Can we take all of them?’” Tezino tells InnovationMap. Continue reading.

Prabhdeep Singh Sekhon, CEO of Gold H2

Prabhdeep Singh Sekhon joins the Houston Innovators Podcast. Photo courtesy of Gold H2

Using microbes to sustainably unlock low-cost hydrogen sounds like the work of science fiction, but one Houston company is doing just that.

Gold H2, a spin-off company from Cemvita, has bioengineered subsurface microbes to use in wells to consume carbon and generate clean hydrogen. The technology was piloted two years ago by Cemvita, and now, as its own company with a new CEO, it's safe to say Gold H2's on its way.

"First of all, that was groundbreaking," Prabhdeep Singh Sekhon, CEO of Gold H2, says of the 2022 pilot in the Permian Basin, "to be able to use bugs to produce hydrogen within a couple of days."

"2024 is supposed to be the year where Gold H2 takes off," Sekhon, who joined the company in April, tells the Houston Innovators Podcast. "It was one of those opportunities that I couldn't turn down. I had been following the company. I thought, 'here is this innovative tech that's on the verge of providing a ground-breaking solution to the energy transition — what better time to join the team.'" Continue reading.

Jill Chapman, director of early talent programs at Insperity

Ultimately, volunteer programs provide a platform for employees to make a positive impact in the community. Photo courtesy of Insperity

Companies of all sizes and stages can implement community-focused initiatives for volunteering, as Jill Chapman of Insperity explains in a guest column.

"Expanding one’s social responsibility doesn’t have to break the bank," she writes. "Smaller companies trying to make an impact should start by establishing initiatives that lay the foundation for a successful volunteer program. To further build out a volunteer program, leaders should look to their employees to define what organizations or causes they are passionate about."

Chapman provides more details on how to introduce volunteering to your workforce. Continue reading.

This week's roundup of Houston innovators includes Emily Keeton of Loeb.nyc, Steve Kean of GHP, and Lacey Tezino of Passport Journeys. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from investing to mental health — recently making headlines in Houston innovation.

Emily Keeton, operating partner and investor of Loeb.nyc

Emily Keeton has worn a lot of hats in Houston's innovation ecosystem and beyond. She shares on the Houston Innovators Podcast how she's engaging with companies these days, what the future holds for Houston, and more. Photo courtesy

Emily Keeton has had a front-row seat as the Houston innovation ecosystem developed — first hands on as a co-founder of Station Houston, and later from outside looking in from New York. As she shared on the Houston Innovators Podcast, she's hopeful about the future of the community.

"I am very optimistic about the future of Houston. It's a long game, and I think people need to keep showing up," she says on the show.

Now based in Houston, her latest endeavor is working with Michael Loeb on Loeb.nyc, a New York-based investment firm with shared services — marketing, design, etc. — with his portfolio. Read more.

Steve Kean, incoming president and CEO of the Greater Houston Partnership

Steve Kean will transition from leading Kinder Morgan to assuming the role of president and CEO of the Greater Houston Partnership later this year. Photo courtesy of the GHP

Steve Kean, who currently serves as the CEO of Kinder Morgan Inc., has been announced as the next president and CEO of the Greater Houston Partnership. He's expected to transition from CEO to board of directors member at Kinder Morgan on August 1. Kean will then assume his new position at GHP no later than Dec. 1.

“I’m grateful for the opportunity to serve our region in this role," he says. "I look forward to building on what Bob, the Board, members, and staff of the Partnership have accomplished. I know first-hand the opportunities that a vibrant business sector can create for people and communities. I look forward to expanding those opportunities further.”

The GHP's outgoing president and CEO, Bob Harvey, announced his retirement earlier this year, and will remain in his position until Kean is onboarded. Read more.

A Houston-founded company is targeting mothers and daughters with their teletherapy app. Photo courtesy of Passport Journeys

When Lacey Tezino’s mother died of cancer she vowed to help other mothers and daughters find their own ways to bond in beautiful, nurturing ways. She turned that vow into a mission that is now available for others to embark on with an online therapy app tailored specifically for the mother-daughter dynamic Passport Journeys.

The app, which launched aptly on Mother's Day, can be downloaded via Apple or Google Play, and includes video therapy sessions, journal opportunities, interactive worksheets, and help those who need access to this form of mental health help with ease.

“Outside of our target audience being mother-daughter, we are also the first teletherapy app to find prescribed activities,“ Tezino tells InnovationMap. “We are the first ones that are actually having the therapist in between their video sessions assign the mother-daughter pair intentional bonding activities. It is meant for them to spend quality time on where they are at in their relationship…there aren’t any other apps that are doing that.” Read more.

A Houston-founded company is targeting mothers and daughters with their teletherapy app. Photo courtesy of Passport Journeys

Houston startup addresses mother-daughter dynamic with first app of its kind

When Lacey Tezino’s mother died of cancer she vowed to help other mothers and daughters find their own ways to bond in beautiful, nurturing ways.

Tezino turned that vow into a mission that is now available for others to embark on with an online therapy app tailored specifically for the mother-daughter dynamic Passport Journeys.

The Houston-based company is billed as the first mother-daughter teletherapy application that stands out in a crowded market place on online therapy like Better Help. Tezino, the founder and CEO, partnered with seven Houston-based licensed behavioral health clinics to make the dream a reality.

The app, which launched aptly on Mother's Day, can be downloaded via Apple or Google Play, and includes video therapy sessions, journal opportunities, interactive worksheets, and help those who need access to this form of mental health help with ease.

“Outside of our target audience being mother-daughter, we are also the first teletherapy app to find prescribed activities,“ Tezino tells InnovationMap. “We are the first ones that are actually having the therapist in between their video sessions assign the mother-daughter pair intentional bonding activities. It is meant for them to spend quality time on where they are at in their relationship…there aren’t any other apps that are doing that.”

According to research from Passport Journeys, there are 85 million mothers in the United States, and the company hopes to help connect mothers and daughters in a flexible, and affordable way that differs from traditional therapy settings in a time where mental health is a priority for many.

“For your mental health in general, having these resources — there are thousands of these apps out there, but having something that is targeted therapy for your relationship is different, and the importance is your relationships ripple through your mental health,” Tezino says. “Fostering and growing this (mother-daughter) relationship is a part of mental health.”

Lacey Tezino founded Passport Journeys to provide a teletherapy platform for mothers and daughters. Photo courtesy

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.